EVIDENCE LIBRARY
Corydalis Rat Probe Study Found Enzyme-Specific Signals Rather Than a Universal Herbal Interaction
A rat pharmacokinetic experiment used midazolam among several probe drugs after herbal exposure. Its findings did not establish the same magnitude of interaction in humans.
A rat pharmacokinetic experiment used midazolam among several probe drugs after herbal exposure. Its findings did not establish the same magnitude of interaction in humans.
The experiment
Rats received Corydalis decumbens or saline for seven days, followed by a probe cocktail. Drug and metabolite measurements used a validated mass-spectrometric method.
The investigators interpreted the patterns as possible inhibition of selected pathways including CYP3A-related handling, with induction of another pathway and little change in some others. Midazolam contributed information to that pathway-specific assessment.
Species and preparation are central
Rat enzymes and their relationship to human CYP pathways are not perfectly interchangeable. The particular herbal preparation, exposure, timing, and probe doses also limit generalization to supplements sold under the same plant name.
A pharmacokinetic signal does not establish sedation, impairment, or an adverse clinical interaction. The study did not enroll patients or establish a reliable human dose-adjustment rule.
Use in a history review
Document herbal products and timing, but avoid assuming that every co-use caused toxicity. This paper supplies preclinical evidence for further interaction assessment, not proof that an individual patient’s midazolam concentration or behavior was changed by Corydalis.
Source paper
Original analysis of the supplied journal article, identified as PMC6360625.